<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936519</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 38115</org_study_id>
    <nct_id>NCT01936519</nct_id>
  </id_info>
  <brief_title>Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.</brief_title>
  <official_title>A Randomized Prospective Trial of Conversion to Everolimus Therapy From Calcineurin Inhibitor Based Maintenance Immunosuppression in Association With Mycophenolic Acid in Liver Transplantation: Examination of Impact on Long Term Renal Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the renal sparing impact of implementing a strategy of conversion to&#xD;
      everolimus from a calcineurin inhibitor based immunosuppressive protocol at 3 months post&#xD;
      liver transplant&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Given the increasing proportion of patients having renal failure at the time of transplant,&#xD;
      with the nephrotoxic effect of calcineurin inhibitor based immunosuppression associated with&#xD;
      its long term negative survival impact, this study proposes to examine the renal sparing&#xD;
      impact of conversion to everolimus from a calcineurin inhibitor based immunosuppressive&#xD;
      protocol at 3 months post liver transplant. The 3 month time point was chosen to allow for&#xD;
      the switch to everolimus to occur at a period of stable post transplant liver function when&#xD;
      both technical and rejection risks are lower. The 3 month cut off was also chosen because of&#xD;
      data indicating that worsening renal function at 4 weeks, 3 months and 1 year post transplant&#xD;
      is an independent risk factor for the development of chronic renal failure and end stage&#xD;
      renal disease after orthotopic liver transplantation. 24 patients will be randomized into 2&#xD;
      arms:&#xD;
&#xD;
      Arm A: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic:&#xD;
      MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.&#xD;
&#xD;
      Arm B: Continuation with standard immunosuppressive therapy consisting of Calcineurin&#xD;
      inhibitor associated with mycophenolic acid (Myfortic: MPA).&#xD;
&#xD;
      Follow up: 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 16, 2013</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Function as Measured by 24 Hour Urine Creatinine Clearance</measure>
    <time_frame>6 months, 1 year, and 2 years</time_frame>
    <description>Renal Function was assessed by 24 hr urine collection creatinine clearance measured (mL/min). 24 Hr urine collection was assessed at baseline, 6 months, 1 year, and 2 years post transplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Function as Measured by Serum Creatinine Level</measure>
    <time_frame>6 months, 1 year, and 2 years</time_frame>
    <description>Serum creatinine levels were assessed at 6 months, 1 year, and 2 years post transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Function as Measured by Cockcroft Gault Creatinine Clearance</measure>
    <time_frame>6 months, 1 year, and 2 years</time_frame>
    <description>The Cockcroft-Gault formula for estimating creatinine clearance was determined at 6 months, 1 year, and 2 years post transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Function as Measured by Modification of Diet in Renal Disease (MDRD) Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>6 months, 1 year, and 2 years</time_frame>
    <description>Modification of Diet in Renal Disease (MDRD) estimated Glomerular Filtration Rate (eGFR) was assessed at 6 months, 1 year, and 2 years post transplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Function as Measured by Iothalamate Clearance</measure>
    <time_frame>6 months, 1 year, and 2 years</time_frame>
    <description>Iothalamate Clearance was assessed at 6 months, 1 year, and 2 years post transplant.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Recipient and Donor Genotyping for Selected Variants of CYP3A5, ABCB1 (MDR1), and CYP4A Genes</measure>
    <time_frame>2 years</time_frame>
    <description>A blood sample was obtained from recipients and donors to measure gene polymorphism effects on metabolism of calcineurin inhibitor and everolimus. The polymorphisms are represented as the number of SNP occurrences for the CYP3A5, ABCB1 (MDR1) gene, and CYP4A4*22 genes.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Immunosuppression</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Calcineurin Inhibitor with Mycophenolic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcineurin inhibitor immunosuppression with mycophenolic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus with Mycophenolic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm A: Everolimus</intervention_name>
    <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
    <arm_group_label>Everolimus with Mycophenolic Acid</arm_group_label>
    <other_name>Zortress; Mycophenolic Acid (Myfortic)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcineurin Inhibitor</intervention_name>
    <description>Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).</description>
    <arm_group_label>Calcineurin Inhibitor with Mycophenolic Acid</arm_group_label>
    <other_name>Tacrolimus (Prograf)</other_name>
    <other_name>Cyclosporine (Gengraf)</other_name>
    <other_name>Mycophenolic Acid (Myfortic)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability and willingness to provide written informed consent and adhere to study&#xD;
             regimen.&#xD;
&#xD;
          -  Primary deceased donor liver transplant recipients 18-70 years of age&#xD;
&#xD;
          -  Functioning allograft at randomization (AST, ALT, Total Bilirubin levels ≤3 times ULN,&#xD;
             and AlkP and GGT levels ≤ 5 times ULN). Elevated GGT alone, in combination with AST,&#xD;
             ALT, total bilirubin and AlkP within defined range does not exclude patients from&#xD;
             randomization.&#xD;
&#xD;
          -  Recipients on an immunosuppressive regimen of corticosteroids and tacrolimus.&#xD;
&#xD;
          -  Confirmed recipient HCV status at Screening (either by serology or PCR).&#xD;
&#xD;
          -  Abbreviated MDRD eGFR ≥ 30 mL/min/1.73m2. Local and central serum creatinine results&#xD;
             within 5 days prior to randomization, however no sooner than Day 25&#xD;
             post-transplantation.&#xD;
&#xD;
          -  Verification of at least one tacrolimus trough level of ≥ 8 ng/mL one week prior to&#xD;
             randomization. Target trough levels above 8 ng/mL prior to randomization.&#xD;
&#xD;
          -  Patients able to take oral medication at time of randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recipients of multiple solid organ or islet cell tissue transplants, or have&#xD;
             previously received an organ or tissue transplant. Combined liver kidney transplant&#xD;
             recipients.&#xD;
&#xD;
          -  Living donor or split liver recipients.&#xD;
&#xD;
          -  History of malignancy of any organ system within past 5 years whether or not there is&#xD;
             evidence of local recurrence or metastases, other than non-metastatic basal or&#xD;
             squamous cell carcinoma of the skin or HCC.&#xD;
&#xD;
          -  Hepatocellular carcinoma that does not fulfill Milan criteria (1 nodule ≤ 5 cm, 2-3&#xD;
             nodules all &lt; 3 cm, per explant histology of recipient liver.&#xD;
&#xD;
          -  Use of antibody induction therapy.&#xD;
&#xD;
          -  Patients with known hypersensitivity to the drugs used on study or their class, or to&#xD;
             any of the excipients.&#xD;
&#xD;
          -  Recipients of ABO incompatible transplant grafts.&#xD;
&#xD;
          -  Recipients of Hepatitis B surface antigen or HIV donor organs.&#xD;
&#xD;
          -  Surgical or medical condition, which might significantly alter absorption,&#xD;
             distribution, metabolism and excretion of study drug.&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP): all women physiologically capable of&#xD;
             becoming pregnant, including women whose career, lifestyle, or sexual orientation&#xD;
             precludes intercourse with a male partner and women whose partners have been&#xD;
             sterilized by vasectomy or other means, UNLESS (1) they meet the following definition&#xD;
             of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of&#xD;
             spontaneous amenorrhea with serum FSH levels &gt;40 mIU/m, or (2) have past 6 weeks from&#xD;
             surgical bilateral oophorectomy with or without hysterectomy or (3) are using one or&#xD;
             more of the following methods of contraception: surgical sterilization (e.g.,&#xD;
             bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch,&#xD;
             oral), copper coated IUD and double-barrier methods ( any double combination of male&#xD;
             or female condom with spermicidal gel, diaphragm, sponge, cervical cap). Periodic&#xD;
             abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and&#xD;
             withdrawal are not acceptable methods of contraception. Reliable contraception should&#xD;
             be maintained throughout and for 3 months after study drug discontinuation.&#xD;
&#xD;
          -  History of coagulopathy or medical condition requiring long-term anticoagulation which&#xD;
             would preclude liver biopsy after transplantation. (Low dose aspirin treatment or&#xD;
             interruption of chronic anticoagulant is allowed).&#xD;
&#xD;
        Enrollment Exclusion - Randomization&#xD;
&#xD;
          -  Severe hypercholesterolemia (&gt;350 mg/dL; &gt;9 mmol/L) or hypertriglyceridemia (&gt;500&#xD;
             mg/dL; &gt;8.5 mmol/L) within 6 months of transplantation. Controlled hyperlipidemia is&#xD;
             acceptable at time of randomization.&#xD;
&#xD;
          -  Platelet count &lt; 50,000/mm3 at randomization.&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 1,000/mm³ or white blood cell count &lt;2,000/mm³ at&#xD;
             randomization.&#xD;
&#xD;
          -  Patients positive for HIV: Negative laboratory results within 6 months before&#xD;
             randomization are acceptable.&#xD;
&#xD;
          -  Clinically significant systemic infection requiring IV antibiotics at randomization.&#xD;
             Patients in a critical care setting at randomization requiring life support measures&#xD;
             such as mechanical ventilation, dialysis, or vasopressor agents.&#xD;
&#xD;
          -  Patients on renal replacement therapy within 7 days prior to randomization.&#xD;
&#xD;
          -  Thrombosis of major hepatic arteries, major hepatic veins, portal vein and inferior&#xD;
             vena cava. Results obtained within 5 days prior to randomization are acceptable,&#xD;
             however no sooner than Day 25 post-transplantation.&#xD;
&#xD;
          -  Acute rejection requiring antibody therapy or more than one steroid sensitive episode&#xD;
             of acute rejection during the run-in period. Includes patients who have not completed&#xD;
             steroid treatment for acute rejection within 7 days prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zakiyah Kadry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine; Penn State Milton S Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State College of Medicine; Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Burra P, Senzolo M, Masier A, Prestele H, Jones R, Samuel D, Villamil F. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. Dig Liver Dis. 2009 May;41(5):350-6. doi: 10.1016/j.dld.2008.09.018. Epub 2008 Nov 28.</citation>
    <PMID>19046932</PMID>
  </reference>
  <reference>
    <citation>Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001 Dec 27;72(12):1934-9.</citation>
    <PMID>11773892</PMID>
  </reference>
  <reference>
    <citation>Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003 Sep 4;349(10):931-40.</citation>
    <PMID>12954741</PMID>
  </reference>
  <reference>
    <citation>Velidedeoglu E, Bloom RD, Crawford MD, Desai NM, Campos L, Abt PL, Markmann JW, Mange KC, Olthoff KM, Shaked A, Markmann JF. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation. 2004 Feb 27;77(4):553-6.</citation>
    <PMID>15084934</PMID>
  </reference>
  <reference>
    <citation>Wadei HM, Geiger XJ, Cortese C, Mai ML, Kramer DJ, Rosser BG, Keaveny AP, Willingham DL, Ahsan N, Gonwa TA. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant. 2008 Dec;8(12):2618-26. doi: 10.1111/j.1600-6143.2008.02426.x.</citation>
    <PMID>19032225</PMID>
  </reference>
  <reference>
    <citation>Randhawa PS, Shapiro R. Chronic renal failure after liver transplantation. Am J Transplant. 2005 May;5(5):967-8.</citation>
    <PMID>15816874</PMID>
  </reference>
  <reference>
    <citation>McCauley J, Van Thiel DH, Starzl TE, Puschett JB. Acute and chronic renal failure in liver transplantation. Nephron. 1990;55(2):121-8.</citation>
    <PMID>2362625</PMID>
  </reference>
  <reference>
    <citation>Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation. 1998 Jul 15;66(1):59-66.</citation>
    <PMID>9679823</PMID>
  </reference>
  <reference>
    <citation>Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, Rostaing L, Rimola A, Marshall S, Mayer AD; ReSpECT Study Group. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant. 2009 Feb;9(2):327-36. doi: 10.1111/j.1600-6143.2008.02493.x. Epub 2008 Dec 15.</citation>
    <PMID>19120077</PMID>
  </reference>
  <reference>
    <citation>Chapman TM, Perry CM. Everolimus. Drugs. 2004;64(8):861-72; discussion 873-4.</citation>
    <PMID>15059040</PMID>
  </reference>
  <reference>
    <citation>Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006 Nov;12(11):1640-8. Erratum in: Liver Transpl. 2006 Nov;12(11):1726.</citation>
    <PMID>16598777</PMID>
  </reference>
  <reference>
    <citation>Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit. 2002 Feb;24(1):53-8. Review.</citation>
    <PMID>11805723</PMID>
  </reference>
  <reference>
    <citation>Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw LM, Munir L, Ulbricht B, Cooper M; CRADUS09 Study Group. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation. 2008 Mar 27;85(6):821-6. doi: 10.1097/TP.0b013e318166927b.</citation>
    <PMID>18360262</PMID>
  </reference>
  <reference>
    <citation>Everson GT. Everolimus and mTOR inhibitors in liver transplantation: opening the &quot;box&quot;. Liver Transpl. 2006 Nov;12(11):1571-3. Review.</citation>
    <PMID>17058246</PMID>
  </reference>
  <reference>
    <citation>De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E, Ducci J, Caneschi F, Coletti L, Campani D, Filipponi F. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int. 2009 Mar;22(3):279-86. doi: 10.1111/j.1432-2277.2008.00768.x. Epub 2008 Dec 2.</citation>
    <PMID>19054383</PMID>
  </reference>
  <reference>
    <citation>Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001 Sep 15;72(5):777-86.</citation>
    <PMID>11571437</PMID>
  </reference>
  <reference>
    <citation>Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF; Rapamune Maintenance Regimen Study Group. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int. 2005 Jan;18(1):22-8. Erratum in: Transpl Int. 2005 Mar;18(3):369.</citation>
    <PMID>15612979</PMID>
  </reference>
  <reference>
    <citation>Ekberg H. Calcineurin inhibitor sparing in renal transplantation. Transplantation. 2008 Sep 27;86(6):761-7. doi: 10.1097/TP.0b013e3181856f39.</citation>
    <PMID>18813097</PMID>
  </reference>
  <reference>
    <citation>Baboolal K. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation. 2003 Apr 27;75(8):1404-8.</citation>
    <PMID>12717239</PMID>
  </reference>
  <reference>
    <citation>Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006 May 15;81(9):1234-48. Review.</citation>
    <PMID>16699448</PMID>
  </reference>
  <reference>
    <citation>Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003 Aug 28;349(9):847-58.</citation>
    <PMID>12944570</PMID>
  </reference>
  <reference>
    <citation>Levy GA, Grant D, Paradis K, Campestrini J, Smith T, Kovarik JM. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation. 2001 Jan 15;71(1):160-3.</citation>
    <PMID>11211186</PMID>
  </reference>
  <reference>
    <citation>Gomez-Camarero J, Salcedo M, Rincon D, Lo Iacono O, Ripoll C, Hernando A, Sanz C, Clemente G, Bañares R. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation. 2007 Sep 27;84(6):786-91.</citation>
    <PMID>17893613</PMID>
  </reference>
  <reference>
    <citation>Yu SF, Wu LH, Zheng SS. Genetic factors for individual administration of immunosuppressants in organ transplantation. Hepatobiliary Pancreat Dis Int. 2006 Aug;5(3):337-44.</citation>
    <PMID>16911928</PMID>
  </reference>
  <reference>
    <citation>Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med. 1996 Jul 15;15(13):1447-58.</citation>
    <PMID>8841654</PMID>
  </reference>
  <reference>
    <citation>Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Econ. 1996 Jul-Aug;5(4):297-305. Erratum in: Health Econ 1999 Sep;8(6):559.</citation>
    <PMID>8880166</PMID>
  </reference>
  <reference>
    <citation>Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997 Jul-Aug;6(4):327-40. Review.</citation>
    <PMID>9285227</PMID>
  </reference>
  <reference>
    <citation>Löthgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ. 2000 Oct;9(7):623-30.</citation>
    <PMID>11103928</PMID>
  </reference>
  <reference>
    <citation>Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl. 2003 Oct;9(10):1079-85.</citation>
    <PMID>14526403</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2013</study_first_posted>
  <results_first_submitted>September 30, 2020</results_first_submitted>
  <results_first_submitted_qc>December 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 12, 2021</results_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Zakiyah Kadry</investigator_full_name>
    <investigator_title>Professor of Surgery; Chief, Division of Transplantation</investigator_title>
  </responsible_party>
  <keyword>Everolimus</keyword>
  <keyword>Zortress</keyword>
  <keyword>Renal Function</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Myfortic</keyword>
  <keyword>Mycophenolic Acid</keyword>
  <keyword>Liver Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to publish de-identified data</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT01936519/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Calcineurin Inhibitor and Mycophenolic Acid</title>
          <description>Calcineurin inhibitor immunosuppression with mycophenolic acid&#xD;
Calcineurin Inhibitor: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).</description>
        </group>
        <group group_id="P2">
          <title>Everolimus and Mycophenolic Acid</title>
          <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.&#xD;
Everolimus: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Calcineurin Inhibitor and Mycophenolic Acid</title>
          <description>Calcineurin inhibitor immunosuppression with mycophenolic acid&#xD;
Calcineurin Inhibitor: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).</description>
        </group>
        <group group_id="B2">
          <title>Everolimus and Mycophenolic Acid</title>
          <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.&#xD;
Everolimus: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" lower_limit="45" upper_limit="69"/>
                    <measurement group_id="B2" value="56.5" lower_limit="37" upper_limit="70"/>
                    <measurement group_id="B3" value="55.79" lower_limit="37" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" lower_limit="0.79" upper_limit="1.78"/>
                    <measurement group_id="B2" value="1.23" lower_limit="0.62" upper_limit="1.8"/>
                    <measurement group_id="B3" value="1.26" lower_limit="0.62" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cockcroft Gault Creatinine Clearance</title>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.11" lower_limit="42.48" upper_limit="144.58"/>
                    <measurement group_id="B2" value="85.15" lower_limit="44.27" upper_limit="175.99"/>
                    <measurement group_id="B3" value="81.63" lower_limit="42.48" upper_limit="175.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modification of Diet in Renal Disease (MDRD) Clearance</title>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.24" lower_limit="40" upper_limit="108.12"/>
                    <measurement group_id="B2" value="69.91" lower_limit="38.2" upper_limit="140.92"/>
                    <measurement group_id="B3" value="65.58" lower_limit="38.2" upper_limit="140.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24 Hour Urine Creatinine Clearance</title>
          <units>mL/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="17" upper_limit="200"/>
                    <measurement group_id="B2" value="59.25" lower_limit="24" upper_limit="99"/>
                    <measurement group_id="B3" value="61.63" lower_limit="17" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Iothalamate Clearance</title>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.60" lower_limit="16.14" upper_limit="141.54"/>
                    <measurement group_id="B2" value="58.10" lower_limit="31.46" upper_limit="110.63"/>
                    <measurement group_id="B3" value="59.35" lower_limit="16.14" upper_limit="141.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24hr Urine Protein</title>
          <units>g/24hrs</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.2" lower_limit="0.039" upper_limit="0.504"/>
                    <measurement group_id="B2" value="0.19" lower_limit="0.055" upper_limit="0.52"/>
                    <measurement group_id="B3" value="0.1925" lower_limit="0.039" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Renal Function as Measured by 24 Hour Urine Creatinine Clearance</title>
        <description>Renal Function was assessed by 24 hr urine collection creatinine clearance measured (mL/min). 24 Hr urine collection was assessed at baseline, 6 months, 1 year, and 2 years post transplant.</description>
        <time_frame>6 months, 1 year, and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcineurin Inhibitor With Mycophenolic Acid</title>
            <description>Calcineurin inhibitor immunosuppression with mycophenolic acid&#xD;
Calcineurin Inhibitor: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).</description>
          </group>
          <group group_id="O2">
            <title>Everolimus With Mycophenolic Acid</title>
            <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.&#xD;
Arm A: Everolimus: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function as Measured by 24 Hour Urine Creatinine Clearance</title>
          <description>Renal Function was assessed by 24 hr urine collection creatinine clearance measured (mL/min). 24 Hr urine collection was assessed at baseline, 6 months, 1 year, and 2 years post transplant.</description>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24hr Urine Creatinine Clearance at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.09" spread="30.08"/>
                    <measurement group_id="O2" value="70.75" spread="29.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24hr Urine Creatinine Clearance at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.09" spread="28.91"/>
                    <measurement group_id="O2" value="86.8" spread="29.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24hr Urine Creatinine Clearance at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.54" spread="27.5"/>
                    <measurement group_id="O2" value="90.63" spread="30.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Function as Measured by Serum Creatinine Level</title>
        <description>Serum creatinine levels were assessed at 6 months, 1 year, and 2 years post transplant</description>
        <time_frame>6 months, 1 year, and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcineurin Inhibitor and Mycophenolic Acid</title>
            <description>Calcineurin inhibitor immunosuppression with mycophenolic acid&#xD;
Calcineurin Inhibitor: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).</description>
          </group>
          <group group_id="O2">
            <title>Everolimus and Mycophenolic Acid</title>
            <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.&#xD;
Everolimus: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function as Measured by Serum Creatinine Level</title>
          <description>Serum creatinine levels were assessed at 6 months, 1 year, and 2 years post transplant</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Creatinine at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.43"/>
                    <measurement group_id="O2" value="1.02" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Creatinine at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.38"/>
                    <measurement group_id="O2" value="0.95" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Creatinine at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.69"/>
                    <measurement group_id="O2" value="0.95" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Function as Measured by Cockcroft Gault Creatinine Clearance</title>
        <description>The Cockcroft-Gault formula for estimating creatinine clearance was determined at 6 months, 1 year, and 2 years post transplant</description>
        <time_frame>6 months, 1 year, and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcineurin Inhibitor and Mycophenolic Acid</title>
            <description>Calcineurin inhibitor immunosuppression with mycophenolic acid&#xD;
Calcineurin Inhibitor: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).</description>
          </group>
          <group group_id="O2">
            <title>Everolimus and Mycophenolic Acid</title>
            <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.&#xD;
Everolimus: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function as Measured by Cockcroft Gault Creatinine Clearance</title>
          <description>The Cockcroft-Gault formula for estimating creatinine clearance was determined at 6 months, 1 year, and 2 years post transplant</description>
          <units>mL/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cockcroft Gault Creatinine Clearance at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.84" spread="29.29"/>
                    <measurement group_id="O2" value="100.17" spread="45.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cockcroft Gault Creatinine Clearance at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.84" spread="37.17"/>
                    <measurement group_id="O2" value="113.47" spread="60.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cockcroft Gault Creatinine Clearance at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.85" spread="28.57"/>
                    <measurement group_id="O2" value="108.16" spread="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the Cockcroft Gault Creatinine clearance 2 year data.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Mann Whitney U Test was performed</non_inferiority_desc>
            <p_value>0.283</p_value>
            <p_value_desc>Cockcroft-Gault Clearance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>27.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>20.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.17</ci_lower_limit>
            <ci_upper_limit>70.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Function as Measured by Modification of Diet in Renal Disease (MDRD) Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>Modification of Diet in Renal Disease (MDRD) estimated Glomerular Filtration Rate (eGFR) was assessed at 6 months, 1 year, and 2 years post transplant.</description>
        <time_frame>6 months, 1 year, and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcineurin Inhibitor and Mycophenolic Acid</title>
            <description>Calcineurin inhibitor immunosuppression with mycophenolic acid&#xD;
Calcineurin Inhibitor: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).</description>
          </group>
          <group group_id="O2">
            <title>Everolimus and Mycophenolic Acid</title>
            <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.&#xD;
Everolimus: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function as Measured by Modification of Diet in Renal Disease (MDRD) Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>Modification of Diet in Renal Disease (MDRD) estimated Glomerular Filtration Rate (eGFR) was assessed at 6 months, 1 year, and 2 years post transplant.</description>
          <units>mL/min/1.73 m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MDRD eGFR at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.18" spread="22.51"/>
                    <measurement group_id="O2" value="81.27" spread="31.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDRD eGFR at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.63" spread="19.68"/>
                    <measurement group_id="O2" value="88.01" spread="34.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDRD eGFR at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.29" spread="17.58"/>
                    <measurement group_id="O2" value="87.37" spread="32.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the MDRD Clearance 2 year data row data.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Wilcoxon Test</non_inferiority_desc>
            <p_value>0.013</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>34.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.95</ci_lower_limit>
            <ci_upper_limit>58.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Function as Measured by Iothalamate Clearance</title>
        <description>Iothalamate Clearance was assessed at 6 months, 1 year, and 2 years post transplant.</description>
        <time_frame>6 months, 1 year, and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcineurin Inhibitor and Mycophenolic Acid</title>
            <description>Calcineurin inhibitor immunosuppression with mycophenolic acid&#xD;
Calcineurin Inhibitor: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).</description>
          </group>
          <group group_id="O2">
            <title>Everolimus and Mycophenolic Acid</title>
            <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.&#xD;
Everolimus: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function as Measured by Iothalamate Clearance</title>
          <description>Iothalamate Clearance was assessed at 6 months, 1 year, and 2 years post transplant.</description>
          <units>mL/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Iothalamate Clearance at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.99" spread="39.23"/>
                    <measurement group_id="O2" value="74.23" spread="31.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iothalamate Clearance at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.65" spread="32.69"/>
                    <measurement group_id="O2" value="104.01" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iothalamate Clearance at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.19" spread="24.75"/>
                    <measurement group_id="O2" value="79.41" spread="27.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the Iothalamate Clearance 2 year data.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Wilcoxon Test</non_inferiority_desc>
            <p_value>0.099</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.28</ci_lower_limit>
            <ci_upper_limit>47.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Power and sample size. The assumption was made that eGFR would improve from 34 mL/min/1.73 m2 to 43 mL/min/1.73 m2. It was determined that a sample size of 12 in each group would have 80% power to detect a difference in means of -9.0 (the difference between a group 1 mean of 34.0 and a group 2 mean of 43.0) assuming that the common standard deviation was 7.5 using a two group t-test with a 0.05 two-sided significance level.&#xD;
Data from the 2 year time point was used for analysis.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-parametric statistical tests were used for all analyses, including the Mann-Whitney U test for continuous outcomes and Pearson's chi-square test for binary outcomes. Univariate statistical tests were used for all comparisons. Cohen's d was utilized for all comparisons to provide information about effect size.</non_inferiority_desc>
            <p_value>.032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>57.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on 2 year data time point.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Difference of zero hypothesized.</non_inferiority_desc>
            <p_value>0.015</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.263</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>-0.003</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Recipient and Donor Genotyping for Selected Variants of CYP3A5, ABCB1 (MDR1), and CYP4A Genes</title>
        <description>A blood sample was obtained from recipients and donors to measure gene polymorphism effects on metabolism of calcineurin inhibitor and everolimus. The polymorphisms are represented as the number of SNP occurrences for the CYP3A5, ABCB1 (MDR1) gene, and CYP4A4*22 genes.</description>
        <time_frame>2 years</time_frame>
        <population>SNP source: rs776746 = CYP3A5 gene; rs1045642, rs1128503 and rs2032582 = ABCB1 (MDR1) gene, and rs35599367=Cyp4A4*22 gene.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcineurin Inhibitor and Mycophenolic Acid</title>
            <description>Calcineurin inhibitor immunosuppression with mycophenolic acid&#xD;
Calcineurin Inhibitor: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).</description>
          </group>
          <group group_id="O2">
            <title>Everolimus and Mycophenolic Acid</title>
            <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.&#xD;
Arm A: Everolimus: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Recipient and Donor Genotyping for Selected Variants of CYP3A5, ABCB1 (MDR1), and CYP4A Genes</title>
          <description>A blood sample was obtained from recipients and donors to measure gene polymorphism effects on metabolism of calcineurin inhibitor and everolimus. The polymorphisms are represented as the number of SNP occurrences for the CYP3A5, ABCB1 (MDR1) gene, and CYP4A4*22 genes.</description>
          <population>SNP source: rs776746 = CYP3A5 gene; rs1045642, rs1128503 and rs2032582 = ABCB1 (MDR1) gene, and rs35599367=Cyp4A4*22 gene.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recipient Genotypes : rs776746 (CYP3A5 gene)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recipient Genotypes : rs1045642 (ABCB1 gene)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recipient Genotypes : rs1128503 (ABCB1 gene)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recipient Genotypes : rs2032582 (ABCB1 gene)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recipient Genotypes : rs35599367 (CYP4A4*22 gene)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Donor Genotypes : rs776746 (CYP3A5 gene)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Donor Genotypes : rs1045642 (ABCB1 gene)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Donor Genotypes : rs1128503 (ABCB1 gene)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Donor Genotypes : rs2032582 (ABCB1 gene)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Donor Genotypes : rs35599367 (Cyp4A4*22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Calcineurin Inhibitor and Mycophenolic Acid</title>
          <description>Calcineurin inhibitor immunosuppression with mycophenolic acid&#xD;
Calcineurin Inhibitor: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).</description>
        </group>
        <group group_id="E2">
          <title>Everolimus and Mycophenolic Acid</title>
          <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.&#xD;
Arm A: Everolimus: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Artery Thrombosis</sub_title>
                <description>Subject was found to have incidentally a hepatic artery thrombosis at 6 months on a CT scan for tumor screening. Liver function tests were normal and patient was asymptomatic.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Nausea</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title vocab="Emesis">Emesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title vocab="Upper Gastrointestin">Upper Gastrointestinal bleed</sub_title>
                <description>Upper gastrointestinal bleeding from duodenal arterio-venous malformation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title vocab="Constipation">Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title vocab="Diarrhea">Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title vocab="Esophagitis">Esophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title vocab="Abdominal Pain">Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Low white cell count</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cellular Rejection</sub_title>
                <description>T-cell mediated liver organ rejection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>antibody mediated rejection</sub_title>
                <description>Donor specific antibody positive level.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <description>Hepatitis c infection recurrence after liver transplantation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Minor Infection</sub_title>
                <description>Minor infections includes: ascites infection, upper respiratory infection, sinusitis, fever, cholangitis, cold/flu.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dental Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Herpes Simplex &amp; Zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <description>Hyperlipidemia requiring treatment</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <description>Low serum magnesium requiring correction</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Low serum calcium level</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Low serum potassium level</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <description>High serum glucose level</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>High serum potassium level requiring correction/treatment</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <description>Edema of the lower extremities and increased weight due to fluid retention</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hepatic Steatosis</sub_title>
                <description>Fatty liver</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>skin cancer</sub_title>
                <description>Squamous and/or basal cell skin cancer</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>Depression requiring treatment &amp;/or psychiatric evaluation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Temor</sub_title>
                <description>Tremor of the upper extremities</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Low Serum Testosterone Level</sub_title>
                <description>Serum Testosterone level was measured at baseline, 6, 12 &amp; 24 months. Was significantly lower at 6 &amp; 12 months in the Everolimus arm and showed a lower trend at 24 months.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <description>Pulmonary hypertension of unknown cause. Treated.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Zakiyah Kadry</name_or_title>
      <organization>Penn State Milton S Hershey Medical Center</organization>
      <phone>717 531 5921</phone>
      <email>zkadry@pennstatehealth.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

